PHARMA BOX LTD

PHARMA BOX LTD

Company Registration Number:
09472900 (England and Wales)

Unaudited abridged accounts for the year ended 30 June 2019

Period of accounts

Start date: 01 July 2018

End date: 30 June 2019

PHARMA BOX LTD

Contents of the Financial Statements

for the Period Ended 30 June 2019

Balance sheet
Notes

PHARMA BOX LTD

Balance sheet

As at 30 June 2019


Notes

2019

2018


£

£
Fixed assets
Tangible assets: 3 223,078 231,249
Total fixed assets: 223,078 231,249
Current assets
Stocks: 42,000 41,832
Debtors:   300,814 159,391
Cash at bank and in hand: 36,023 157,319
Total current assets: 378,837 358,542
Creditors: amounts falling due within one year:   (360,492) (339,035)
Net current assets (liabilities): 18,345 19,507
Total assets less current liabilities: 241,423 250,756
Creditors: amounts falling due after more than one year:   (239,957) (250,341)
Provision for liabilities: (1,366) (315)
Total net assets (liabilities): 100 100
Capital and reserves
Called up share capital: 100 100
Shareholders funds: 100 100

The notes form part of these financial statements

PHARMA BOX LTD

Balance sheet statements

For the year ending 30 June 2019 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 02 March 2020
and signed on behalf of the board by:

Name: Imran Skhawat
Status: Director

The notes form part of these financial statements

PHARMA BOX LTD

Notes to the Financial Statements

for the Period Ended 30 June 2019

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Revenue recognitionTurnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts. The company recognises revenue when: The amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities

Tangible fixed assets and depreciation policy

Fixtures and fittings 15% Reducing balance,Office equipment, 25% Straight line,Freehold Property 2% Straight line.

Valuation and information policy

StocksStocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method. The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Other accounting policies

Tax:The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.Cash and cash equivalents:Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.Trade debtors:Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.Trade creditors:Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities. Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest methodBorrowings:Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing. Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges. Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.Leases:Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.Share capital:Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.Dividends:Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.Defined contribution pension obligation:the Company operates a defined contribution pension scheme. A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. Contributions to defined contribution plans are charged to profit and loss in the period when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

PHARMA BOX LTD

Notes to the Financial Statements

for the Period Ended 30 June 2019

2. Employees

2019 2018
Average number of employees during the period 12 14

PHARMA BOX LTD

Notes to the Financial Statements

for the Period Ended 30 June 2019

3. Tangible Assets

Total
Cost £
At 01 July 2018 235,362
Additions 749
At 30 June 2019 236,111
Depreciation
At 01 July 2018 4,113
Charge for year 8,920
At 30 June 2019 13,033
Net book value
At 30 June 2019 223,078
At 30 June 2018 231,249

Included within the net book value of land and buildings above is £197,627 (2018 - £201,695) in respect of freehold land and buildings.

PHARMA BOX LTD

Notes to the Financial Statements

for the Period Ended 30 June 2019

4. Financial commitments

Amounts not provided for in the balance sheetThe total amount of financial commitments not included in the balance sheet is £489 (2018 £27,632). Amounts disclosed in the balance sheetIncluded in the balance sheet are financial commitments of £239,957 (2018 £250,341). Lloyd Bank loan secured by floating charge on the Freehold Property

PHARMA BOX LTD

Notes to the Financial Statements

for the Period Ended 30 June 2019

5. Related party transactions

The directors' remuneration for the year was as follows: £25,425 (2018-£24,678)